Natixis’s Aldeyra Therapeutics ALDX Stock Holding History

Natixis’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-674,549	Closed	-$6.7M	–	1013
2023 Q1	$6.7M	Buy	674,549 +630,291	+1,424%	+$4.46M	0.06%	234
2022 Q4	$308K	Buy	+44,258	New	+$253K	﹤0.01%	774

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Natixis's ALDX Position: Q2 2023 in Review

Natixis sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 674,549 shares — an estimated $6.7M sold.

Natixis first reported a position in ALDX in Q4 2022 and held it in 2 quarters. The position peaked at $6.7M in Q1 2023. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.

Natixis reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
Natixis sold 674,549 Aldeyra Therapeutics shares in Q2 2023, an estimated $6.7M.
Natixis first reported a position in Aldeyra Therapeutics in Q4 2022 and held it in 2 quarters.
Natixis's Aldeyra Therapeutics position peaked at $6.7M in Q1 2023.
119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.

Based on Natixis's 13F filing for Q2 2023, filed 11 Aug 2023.